It's simply a violation ... to try to mislead regulators at the federal level in an effort to keep generic drugs, which are typically 25 percent cheaper, off the market, ... If they can delay competition for generic drugs they can reap a lot of gain as a result. We wouldn't file a lawsuit if we didn't think there was a merit to it.
|